These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 21732108)
1. Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines? Emonds KM; Swinnen JV; van Weerden WM; Vanderhoydonc F; Nuyts J; Mortelmans L; Mottaghy FM Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1842-53. PubMed ID: 21732108 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model. Emonds KM; Swinnen JV; Lerut E; Koole M; Mortelmans L; Mottaghy FM EJNMMI Res; 2013 Apr; 3(1):31. PubMed ID: 23618081 [TBL] [Abstract][Full Text] [Related]
3. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. Hara T; Bansal A; DeGrado TR Nucl Med Biol; 2006 Nov; 33(8):977-84. PubMed ID: 17127170 [TBL] [Abstract][Full Text] [Related]
4. MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model. Oyama N; Kim J; Jones LA; Mercer NM; Engelbach JA; Sharp TL; Welch MJ Nucl Med Biol; 2002 Nov; 29(8):783-90. PubMed ID: 12453586 [TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
6. Increased choline uptake in macrophages and prostate cancer cells does not allow for differentiation between benign and malignant prostate pathologies. Schwarz T; Seidl C; Schiemann M; Senekowitsch-Schmidtke R; Krause BJ Nucl Med Biol; 2016 Jun; 43(6):355-9. PubMed ID: 27260776 [TBL] [Abstract][Full Text] [Related]
7. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555 [TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography for prostate, bladder, and renal cancer. Schöder H; Larson SM Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005 [TBL] [Abstract][Full Text] [Related]
9. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. Jadvar H J Nucl Med; 2011 Jan; 52(1):81-9. PubMed ID: 21149473 [TBL] [Abstract][Full Text] [Related]
10. Influence of free fatty acids on glucose uptake in prostate cancer cells. Andersen KF; Divilov V; Sevak K; Koziorowski J; Lewis JS; Pillarsetty N Nucl Med Biol; 2014 Mar; 41(3):254-8. PubMed ID: 24440212 [TBL] [Abstract][Full Text] [Related]
11. Roppongi M; Izumisawa M; Terasaki K; Muraki Y; Shozushima M Ann Nucl Med; 2019 Apr; 33(4):237-243. PubMed ID: 30588580 [TBL] [Abstract][Full Text] [Related]
13. Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis. Ouyang Q; Duan Z; Lei J; Jiao G Tumour Biol; 2016 Mar; 37(3):2999-3007. PubMed ID: 26415734 [TBL] [Abstract][Full Text] [Related]
14. Comparison of 11C-choline with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study. Golan S; Sopov V; Baniel J; Groshar D J Urol; 2011 Aug; 186(2):436-41. PubMed ID: 21679983 [TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476 [TBL] [Abstract][Full Text] [Related]
16. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. Picchio M; Messa C; Landoni C; Gianolli L; Sironi S; Brioschi M; Matarrese M; Matei DV; De Cobelli F; Del Maschio A; Rocco F; Rigatti P; Fazio F J Urol; 2003 Apr; 169(4):1337-40. PubMed ID: 12629355 [TBL] [Abstract][Full Text] [Related]
17. Positron-emission tomography in imaging and staging prostate cancer. Farsad M; Schiavina R; Franceschelli A; Sanguedolce F; Castellucci P; Bertaccini A; Brunocilla E; Manferrari F; Concetti S; Garofalo M; Rocca C; Borghesi M; Franchi R; Fanti S; Nanni C; Martorana G Cancer Biomark; 2008; 4(4-5):277-84. PubMed ID: 18957716 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC). Henriksen G; Herz M; Hauser A; Schwaiger M; Wester HJ Nucl Med Biol; 2004 Oct; 31(7):851-8. PubMed ID: 15464386 [TBL] [Abstract][Full Text] [Related]
19. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702 [TBL] [Abstract][Full Text] [Related]
20. Imaging a pancreatic carcinoma xenograft model with 11C-acetate: a comparison study with 18F-FDG. Zhao C; Chen Z; Ye X; Zhang Y; Zhan H; Aburano T; Tian M; Zhang H Nucl Med Commun; 2009 Dec; 30(12):971-7. PubMed ID: 19696689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]